BioGaia AB (publ) (BIOG-B.ST)
SEK 110.5
(0.82%)
SEK 110.5
(0.82%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 365.35 Million SEK | -2.25% |
| 2022 | 373.77 Million SEK | 90.44% |
| 2021 | 196.27 Million SEK | 9.2% |
| 2020 | 179.73 Million SEK | -4.07% |
| 2019 | 187.34 Million SEK | -12.82% |
| 2018 | 214.89 Million SEK | 19.01% |
| 2017 | 180.56 Million SEK | -20.65% |
| 2016 | 227.56 Million SEK | 87.44% |
| 2015 | 121.4 Million SEK | -17.64% |
| 2014 | 147.4 Million SEK | 138.82% |
| 2013 | 61.72 Million SEK | -81.12% |
| 2012 | 326.97 Million SEK | 328.14% |
| 2011 | 76.36 Million SEK | 61.91% |
| 2010 | 47.16 Million SEK | 30.86% |
| 2009 | 36.04 Million SEK | -0.21% |
| 2008 | 36.12 Million SEK | 83.74% |
| 2007 | 19.65 Million SEK | 622.76% |
| 2006 | 2.72 Million SEK | 113.72% |
| 2005 | -19.82 Million SEK | -185.27% |
| 2004 | 23.25 Million SEK | 78.09% |
| 2003 | 13.05 Million SEK | -66.15% |
| 2002 | 38.56 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 121.84 Million SEK | 80.89% |
| 2024 Q2 | 111.01 Million SEK | -8.89% |
| 2024 Q3 | 36.6 Million SEK | -67.03% |
| 2023 FY | 365.35 Million SEK | -2.25% |
| 2023 Q2 | 80.54 Million SEK | -30.53% |
| 2023 Q1 | 115.94 Million SEK | -16.84% |
| 2023 Q4 | 67.35 Million SEK | -33.64% |
| 2023 Q3 | 101.5 Million SEK | 26.01% |
| 2022 Q2 | 78.54 Million SEK | 2.95% |
| 2022 Q3 | 79.5 Million SEK | 1.22% |
| 2022 FY | 373.77 Million SEK | 90.44% |
| 2022 Q1 | 76.29 Million SEK | 99.34% |
| 2022 Q4 | 139.42 Million SEK | 75.37% |
| 2021 Q4 | 38.27 Million SEK | -27.57% |
| 2021 FY | 196.27 Million SEK | 9.2% |
| 2021 Q1 | 50.44 Million SEK | 31.13% |
| 2021 Q2 | 54.71 Million SEK | 8.46% |
| 2021 Q3 | 52.84 Million SEK | -3.41% |
| 2020 Q4 | 38.46 Million SEK | 87.8% |
| 2020 Q1 | 41.74 Million SEK | -20.55% |
| 2020 Q2 | 79.03 Million SEK | 89.31% |
| 2020 Q3 | 20.48 Million SEK | -74.08% |
| 2020 FY | 179.73 Million SEK | -4.07% |
| 2019 Q3 | 38.04 Million SEK | -37.7% |
| 2019 FY | 187.34 Million SEK | -12.82% |
| 2019 Q1 | 35.69 Million SEK | -37.43% |
| 2019 Q4 | 52.54 Million SEK | 38.13% |
| 2019 Q2 | 61.06 Million SEK | 71.05% |
| 2018 Q2 | 62.75 Million SEK | 45.41% |
| 2018 Q4 | 57.04 Million SEK | 10.87% |
| 2018 FY | 214.89 Million SEK | 19.01% |
| 2018 Q1 | 43.15 Million SEK | -10.75% |
| 2018 Q3 | 51.45 Million SEK | -18.0% |
| 2017 Q1 | 42.88 Million SEK | -8.7% |
| 2017 Q4 | 48.35 Million SEK | 14.73% |
| 2017 Q3 | 42.14 Million SEK | -10.67% |
| 2017 FY | 180.56 Million SEK | -20.65% |
| 2017 Q2 | 47.18 Million SEK | 10.01% |
| 2016 Q4 | 46.97 Million SEK | 33.98% |
| 2016 Q2 | 38.56 Million SEK | 13.88% |
| 2016 Q1 | 33.86 Million SEK | 55.23% |
| 2016 FY | 227.56 Million SEK | 87.44% |
| 2016 Q3 | 35.06 Million SEK | -9.09% |
| 2015 Q1 | 43.23 Million SEK | 141.66% |
| 2015 FY | 121.4 Million SEK | -17.64% |
| 2015 Q4 | 21.81 Million SEK | 5.55% |
| 2015 Q3 | 20.66 Million SEK | -42.09% |
| 2015 Q2 | 35.69 Million SEK | -17.43% |
| 2014 Q2 | 17.76 Million SEK | -81.73% |
| 2014 Q3 | 14.54 Million SEK | -18.12% |
| 2014 Q4 | 17.88 Million SEK | 22.98% |
| 2014 Q1 | 97.2 Million SEK | 496.36% |
| 2014 FY | 147.4 Million SEK | 138.82% |
| 2013 FY | 61.72 Million SEK | -81.12% |
| 2013 Q2 | 15.28 Million SEK | -8.52% |
| 2013 Q4 | 16.3 Million SEK | 21.39% |
| 2013 Q3 | 13.42 Million SEK | -12.15% |
| 2013 Q1 | 16.7 Million SEK | 12.48% |
| 2012 Q4 | 14.85 Million SEK | 7.26% |
| 2012 Q3 | 13.84 Million SEK | -10.41% |
| 2012 Q2 | 15.45 Million SEK | -94.54% |
| 2012 Q1 | 283.19 Million SEK | 1287.33% |
| 2012 FY | 326.97 Million SEK | 328.14% |
| 2011 Q4 | 20.41 Million SEK | 30.99% |
| 2011 Q1 | 18.48 Million SEK | 45.05% |
| 2011 Q2 | 23.69 Million SEK | 28.23% |
| 2011 Q3 | 15.58 Million SEK | -34.24% |
| 2011 FY | 76.36 Million SEK | 61.91% |
| 2010 Q1 | 12.2 Million SEK | 80.45% |
| 2010 Q3 | 8.04 Million SEK | -43.1% |
| 2010 FY | 47.16 Million SEK | 30.86% |
| 2010 Q2 | 14.13 Million SEK | 15.86% |
| 2010 Q4 | 12.74 Million SEK | 58.41% |
| 2009 Q2 | 11.18 Million SEK | 7.23% |
| 2009 Q1 | 10.43 Million SEK | 0.0% |
| 2009 FY | 36.04 Million SEK | -0.21% |
| 2009 Q4 | 6.76 Million SEK | -11.85% |
| 2009 Q3 | 7.67 Million SEK | -31.42% |
| 2008 Q2 | 14.11 Million SEK | 0.0% |
| 2008 FY | 36.12 Million SEK | 83.74% |
| 2007 FY | 19.65 Million SEK | 622.76% |
| 2006 FY | 2.72 Million SEK | 113.72% |
| 2005 FY | -19.82 Million SEK | -185.27% |
| 2004 FY | 23.25 Million SEK | 78.09% |
| 2003 FY | 13.05 Million SEK | -66.15% |
| 2002 FY | 38.56 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 2768.556% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | 1083.001% |
| Enzymatica AB (publ) | -49.72 Million SEK | 834.701% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | 918.936% |
| Gabather AB (publ) | -9.43 Million SEK | 3971.485% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | 1120.993% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | 1832.101% |
| Nanexa AB (publ) | -76.39 Million SEK | 578.222% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | 2471.646% |
| ODI Pharma AB | 355.97 Thousand SEK | -102535.327% |
| Orexo AB (publ) | -128.3 Million SEK | 384.764% |
| Probi AB (publ) | 16.81 Million SEK | -2072.258% |
| Swedencare AB (publ) | 58.6 Million SEK | -523.468% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 84.834% |
| Toleranzia AB | -7.45 Million SEK | 4998.136% |
| Vivesto AB | -367.03 Million SEK | 199.543% |